Your browser doesn't support javascript.
loading
Bicyclic Heterocyclic Replacement of an Aryl Amide Leading to Potent and Kinase-Selective Adaptor Protein 2-Associated Kinase 1 Inhibitors.
Hartz, Richard A; Ahuja, Vijay T; Nara, Susheel J; Kumar, C M Vijaya; Manepalli, Raju K V L P; Sarvasiddhi, Sarat Kumar; Honkhambe, Swarnamba; Patankar, Vidya; Dasgupta, Bireshwar; Rajamani, Ramkumar; Muckelbauer, Jodi K; Camac, Daniel M; Ghosh, Kaushik; Pokross, Matthew; Kiefer, Susan E; Brown, Jeffrey M; Hunihan, Lisa; Gulianello, Michael; Lewis, Martin; Lippy, Jonathan S; Surti, Neha; Hamman, Brian D; Allen, Jason; Kostich, Walter A; Bronson, Joanne J; Macor, John E; Dzierba, Carolyn D.
Afiliación
  • Hartz RA; Department of Small Molecule Drug Discovery, Bristol Myers Squibb Company, Research and Development, 5 Research Parkway, Wallingford, Connecticut 06492, United States.
  • Ahuja VT; Department of Small Molecule Drug Discovery, Bristol Myers Squibb Company, Research and Development, 5 Research Parkway, Wallingford, Connecticut 06492, United States.
  • Nara SJ; Biocon-Bristol Myers Squibb Research and Development Center, Biocon Park, Plot No. 2 & 3, Bommasandra Phase IV, Jigani Link Road, Bangalore 560099, India.
  • Kumar CMV; Biocon-Bristol Myers Squibb Research and Development Center, Biocon Park, Plot No. 2 & 3, Bommasandra Phase IV, Jigani Link Road, Bangalore 560099, India.
  • Manepalli RKVLP; Biocon-Bristol Myers Squibb Research and Development Center, Biocon Park, Plot No. 2 & 3, Bommasandra Phase IV, Jigani Link Road, Bangalore 560099, India.
  • Sarvasiddhi SK; Biocon-Bristol Myers Squibb Research and Development Center, Biocon Park, Plot No. 2 & 3, Bommasandra Phase IV, Jigani Link Road, Bangalore 560099, India.
  • Honkhambe S; Biocon-Bristol Myers Squibb Research and Development Center, Biocon Park, Plot No. 2 & 3, Bommasandra Phase IV, Jigani Link Road, Bangalore 560099, India.
  • Patankar V; Biocon-Bristol Myers Squibb Research and Development Center, Biocon Park, Plot No. 2 & 3, Bommasandra Phase IV, Jigani Link Road, Bangalore 560099, India.
  • Dasgupta B; Department of Small Molecule Drug Discovery, Bristol Myers Squibb Company, Research and Development, 5 Research Parkway, Wallingford, Connecticut 06492, United States.
  • Rajamani R; Department of Molecular Structure and Design, Bristol Myers Squibb Company, Research and Development, 5 Research Parkway, Wallingford, Connecticut 06492, United States.
  • Muckelbauer JK; Department of Molecular Structure and Design, Bristol Myers Squibb Company, Research and Development, P.O. Box 5400, Princeton, New Jersey 08543, United States.
  • Camac DM; Department of Molecular Structure and Design, Bristol Myers Squibb Company, Research and Development, P.O. Box 5400, Princeton, New Jersey 08543, United States.
  • Ghosh K; Biocon-Bristol Myers Squibb Research and Development Center, Biocon Park, Plot No. 2 & 3, Bommasandra Phase IV, Jigani Link Road, Bangalore 560099, India.
  • Pokross M; Department of Molecular Structure and Design, Bristol Myers Squibb Company, Research and Development, P.O. Box 5400, Princeton, New Jersey 08543, United States.
  • Kiefer SE; Department of Protein Science, Bristol Myers Squibb Company, Research and Development, P.O. Box 5400, Princeton, New Jersey 08543, United States.
  • Brown JM; Department of Neuroscience Discovery Biology, Bristol Myers Squibb Company, Research and Development, 5 Research Parkway, Wallingford, Connecticut 06492, United States.
  • Hunihan L; Department of Neuroscience Discovery Biology, Bristol Myers Squibb Company, Research and Development, 5 Research Parkway, Wallingford, Connecticut 06492, United States.
  • Gulianello M; Department of Neuroscience Discovery Biology, Bristol Myers Squibb Company, Research and Development, 5 Research Parkway, Wallingford, Connecticut 06492, United States.
  • Lewis M; Department of Neuroscience Discovery Biology, Bristol Myers Squibb Company, Research and Development, 5 Research Parkway, Wallingford, Connecticut 06492, United States.
  • Lippy JS; Department of Lead Evaluation, Bristol Myers Squibb Company, Research and Development, P.O. Box 5400, Princeton, New Jersey 08543, United States.
  • Surti N; Department of Lead Evaluation, Bristol Myers Squibb Company, Research and Development, P.O. Box 5400, Princeton, New Jersey 08543, United States.
  • Hamman BD; Lexicon Pharmaceuticals, 8800 Technology Forest Place, The Woodlands, Texas 77381, United States.
  • Allen J; Lexicon Pharmaceuticals, 8800 Technology Forest Place, The Woodlands, Texas 77381, United States.
  • Kostich WA; Department of Neuroscience Discovery Biology, Bristol Myers Squibb Company, Research and Development, 5 Research Parkway, Wallingford, Connecticut 06492, United States.
  • Bronson JJ; Department of Small Molecule Drug Discovery, Bristol Myers Squibb Company, Research and Development, 5 Research Parkway, Wallingford, Connecticut 06492, United States.
  • Macor JE; Department of Small Molecule Drug Discovery, Bristol Myers Squibb Company, Research and Development, 5 Research Parkway, Wallingford, Connecticut 06492, United States.
  • Dzierba CD; Department of Small Molecule Drug Discovery, Bristol Myers Squibb Company, Research and Development, 5 Research Parkway, Wallingford, Connecticut 06492, United States.
J Med Chem ; 65(5): 4121-4155, 2022 03 10.
Article en En | MEDLINE | ID: mdl-35171586
ABSTRACT
Adaptor protein 2-associated kinase 1 (AAK1) is a serine/threonine kinase that was identified as a therapeutic target for the potential treatment of neuropathic pain. Inhibition of AAK1 in the central nervous system, particularly within the spinal cord, was found to be the relevant site for achieving an antinociceptive effect. We previously reported that compound 7 is a brain-penetrant, AAK1 inhibitor that showed efficacy in animal models for neuropathic pain. One approach we took to improve upon the potency of 7 involved tying the amide back into the neighboring phenyl ring to form a bicyclic heterocycle. Investigation of the structure-activity relationships (SARs) of substituents on the resultant quinazoline and quinoline ring systems led to the identification of (S)-31, a brain-penetrant, AAK1-selective inhibitor with improved enzyme and cellular potency compared to 7. The synthesis, SAR, and in vivo evaluation of a series of quinazoline and quinoline-based AAK1 inhibitors are described herein.
Asunto(s)

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Quinolinas / Neuralgia Tipo de estudio: Risk_factors_studies Límite: Animals Idioma: En Revista: J Med Chem Asunto de la revista: QUIMICA Año: 2022 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Quinolinas / Neuralgia Tipo de estudio: Risk_factors_studies Límite: Animals Idioma: En Revista: J Med Chem Asunto de la revista: QUIMICA Año: 2022 Tipo del documento: Article País de afiliación: Estados Unidos
...